GW Pharmaceuticals Announce Positive Phase II Trials of Sativex Oromucosal Spray for Multiple Sclerosis
The MS spasticity study, which evaluated 337 patients over a 15 week period, showed a significant reduction in symptoms of spasticity in patients in the 'per protocol' population (i.e. those patients who complied with the study protocol) with advanced MS who had severe levels of spasticity despite ongoing treatment with the best available anti-spasticity medications. In addition 36% of these patients reported at least a 30% improvement in their spasticity symptoms which was also statistically significant.
Additionally, Sativex also had positive impact on other symptoms such as sleep assessments at clinic visits; a timed 10-metre walk, quality of life measures, spasm severity and bladder symptoms.
Source: GH Pharmaceuticals
.jpg)
Comment Preview